Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy
NAR Cancer · 11.01.2023 · 5 (1)
DOI: 10.1093/narcan/zcad005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift NAR Cancer, online erschienen am 06.02.2023. Verfasst von Jay Anand und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 614 Brinkhous-Bullitt Building, Chapel Hill, NC 27599, …. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 265 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIEHS NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
DNA damage tolerance and mutagenesis are hallmarks and enabling characteristics of neoplastic cells that drive tumorigenesis and allow cancer cells to resist therapy. The ‘Y-family’ trans-lesion synthesis (TLS) DNA polymerases enable cells to replicate damaged genomes, thereby conferring DNA damage tolerance. Moreover, Y-family DNA polymerases are inherently error-prone and cause mutations. Therefore, TLS DNA polymerases are potential mediators of important tumorigenic phenotypes. The skin cancer-propensity syndrome xeroderma pigmentosum-variant (XPV) results from defects in the Y-family DNA Polymerase Pol eta (Polη) and compensatory deployment of alternative inappropriate DNA polymerases. However, the extent to which dysregulated TLS contributes to the underlying etiology of other human cancers is unclear. Here we consider the broad impact of TLS polymerases on tumorigenesis and cancer therapy. We survey the ways in which TLS DNA polymerases are pathologically altered in cancer. We summarize evidence that TLS polymerases shape cancer genomes, and review studies implicating dysregulated TLS as a driver of carcinogenesis. Because many cancer treatment regimens comprise DNA-damaging agents, pharmacological inhibition of TLS is an attractive strategy for sensitizing tumors to genotoxic therapies. Therefore, we discuss the pharmacological tractability of the TLS pathway and summarize recent progress on development of TLS inhibitors for therapeutic purposes.
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 614 Brinkhous-Bullitt Building, Chapel Hill, NC 27599, USA.
- Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.
- Department of Biostatistics, University of North Carolina at Chapel Hill, 135 Dauer Drive, 3101 McGavran-Greenberg Hall, Chapel Hill, NC 27599, USA.
- Department of Chemistry, Duke University, Durham, NC 27708, USA.
Förderung
- NCI NIH HHS
- NIEHS NIH HHS
- NCATS NIH HHS
- NIGMS NIH HHS
- National Cancer Institute
- National Institute of Environmental Health Sciences
- Duke Clinical and Translational Science Institute
- Duke Cancer Institute
Zitieren
APA
Anand, J., Chiou, L., Sciandra, C., Zhang, X., Hong, J., Wu, D., Zhou, P., & Vaziri, C. (2023). Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy. NAR Cancer, 5(1). https://doi.org/10.1093/narcan/zcad005
Vancouver
Anand J, Chiou L, Sciandra C, Zhang X, Hong J, Wu D, et al. Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy. NAR Cancer. 2023;5(1). doi:10.1093/narcan/zcad005
BibTeX
@article{Anand2023,
author = {Anand, Jay and Chiou, Lilly and Sciandra, Carly and Zhang, Xingyuan and Hong, Jiyong and Wu, Di and Zhou, Pei and Vaziri, Cyrus},
title = {Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy},
journal = {NAR Cancer},
year = {2023},
volume = {5},
number = {1},
doi = {10.1093/narcan/zcad005}
}
EUVIMED